The FDA approved a supplemental new drug application for ruxolitinib cream 1.5% for the short-term and noncontinuous ...

Arcutis Biotherapeutics (ARQT) announced that new data on Zoryve efficacy across three common skin conditions-seborrheic dermatitis, atopic ...

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin typesNew ...

Dry skin around the nose, a common issue worsened by environmental factors and skin conditions, can be effectively managed ...

ZORYVE Allure Best of Beauty Product Image Allure Best of Beauty Breakthrough Award Winner ZORYVE (roflumilast) cream 0.15%; ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Arcutis Biotherapeutics, ...

Arcutis Biotherapeutics, Inc. ( NASDAQ: ARQT) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 2:35 PM EDT ...

If you are one of the many who have dandruff, you know how rough it can be. Per Mayo Clinic, dandruff is a common but “mild ...

The rising incidence of fungal infections and increasing resistance to antifungal treatments present significant global ...

Here, she says, are seven issues even experts “often” miss in skin of colour: “ Inflammation in skin of colour often triggers ...

Dandruff is an inflammatory condition of the skin of the scalp, with white to yellow, greasy scaling flakes on the surface.

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering ...